Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up
| Autor: | Peter Lanning, Maila Koivisto, T. Paavilainen, Timo Saarela |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Heart disease medicine.medical_treatment Kidney chemistry.chemical_compound Furosemide medicine Humans Diuretics Ultrasonography Heart Failure Creatinine business.industry Infant medicine.disease Urinary calcium Surgery Nephrocalcinosis chemistry Heart failure Pediatrics Perinatology and Child Health Calcium Female Diuretic business medicine.drug Kidney disease |
| Zdroj: | European Journal of Pediatrics. 158:668-672 |
| ISSN: | 1432-1076 0340-6199 |
| Popis: | In order to study the incidence and course of nephrocalcinosis in full-term infants with congestive heart failure receiving long-term furosemide treatment, 36 such infants (median age 2.9 months, range 1.2–8.0) and 36 full-term control infants not receiving any diuretics (median age 3.4 months, range 1.1–8.4) were studied by renal ultrasonography and random urine calcium variables. The infants with nephrocalcinosis were followed at 3–6 month intervals up to 2 years of age, or until ultrasonic resolution. Nephrocalcinosis was found in 5 out of the 36 (14%) treated infants, but in none of the controls (P = 0.03). The dose of furosemide was higher in the infants with nephrocalcinosis than in those without (1.9 ± 0.6 vs. 1.3 ± 0.4 mg/kg per day; P = 0.01). The urinary calcium concentration was higher in the infants receiving furosemide than in& controls and a similar trend was observed in the urinary calcium/creatinine ratio, but& these variables did not differ between the study infants with and without nephrocalcinosis. Ultrasonic resolution of nephrocalcinosis was observed in 3 of the 5& infants at 12 months, but in the other 2 the condition still persisted at 24 months. Conclusions Long-term furosemide treatment in full-term infants with congestive heart failure entails a considerable risk of developing nephrocalcinosis. Renal ultrasonography is warranted in these patients within a few months after initiation of the treatment and in the case of nephrocalcinosis alteration of the diuretic regimen is to be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|